An approval ishighly anticipatedafter the drugmakers said in March that the vaccine had been found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial.
Responding to a Reuters request for comment, the FDA said its review of expanding the vaccine’s emergency use authorization was continuing, but it did not provide further details.
The vaccine has already been cleared in the United States for people age 16 and above.